Toggle Main Menu Toggle Search

Open Access padlockePrints

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis

Lookup NU author(s): Professor Chris LambORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

BackgroundInfliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation.AimTo establish outcomes following anti-TNF withdrawal for sustained remission using new data from a large UK cohort, and assimilation of all available literature for systematic review and meta-analysis.MethodsA retrospective observational study was performed on 166 patients with IBD (146 with Crohn's disease (CD) and 20 with ulcerative colitis [UC) and IBD unclassified (IBDU)] withdrawn from anti-TNF for sustained remission. Meta-analysis was undertaken of all published studies incorporating 11 further cohorts totalling 746 patients (624 CD, 122 UC).ResultsRelapse rates in the UK cohort were 36% by 1 year and 56% by 2 years for CD, and 42% by 1 year and 47% by 2 years for UC/IBDU. Increased relapse risk in CD was associated with age at diagnosis [hazard ratio (HR) 2.78 for age <22 years], white cell count (HR 3.22 for >5.25 x 10(9)/L) and faecal calprotectin (HR 2.95 for >50 g/g) at drug withdrawal. Neither continued immunomodulators nor endoscopic remission were predictors. In the meta-analysis, estimated 1-year relapse rates were 39% and 35% for CD and UC/IBDU respectively. Retreatment with anti-TNF was successful in 88% for CD and 76% UC/IBDU.ConclusionsAssimilation of all available data reveals remarkable homogeneity. Approximately one-third of patients with IBD flare within 12 months of withdrawal of anti-TNF therapy for sustained remission.


Publication metadata

Author(s): Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P, UK Anti-TNF withdrawal study group, Lees CW

Publication type: Article

Publication status: Published

Journal: Alimentary Pharmacology & Therapeutics

Year: 2016

Volume: 43

Issue: 8

Pages: 910-923

Print publication date: 01/04/2016

Online publication date: 19/02/2016

Acceptance date: 14/01/2016

Date deposited: 12/05/2016

ISSN (print): 0269-2813

ISSN (electronic): 1365-2036

Publisher: John Wiley & Sons Ltd.

URL: http://dx.doi.org/10.1111/apt.13547

DOI: 10.1111/apt.13547


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Dr Falk
Falk
Ferring
Genentech/Roche
Shire
Warner-Chilcott
Abbvie
Actavis
Hospira
MSD
Pharmacosmos
Takeda
093885/Z/10/ZWellcome Trust
097943Wellcome Trust

Share